Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial

American Society of Clinical Oncology (ASCO) - Tập 18 Số 3 - Trang 623-623 - 2000
Philip Bonomi1, KyungMann Kim1, Diane L. Fairclough1, David Cella1, John W. Kugler1, Eric K. Rowinsky1, Michael R. Jiroutek1, David C. Johnson1
1From the Rush-Presbyterian St. Luke’s Medical CenterChicago; Illinois Oncology Research Association, Peoria; and Evanston Northwestern Health Care, Northwestern University, Evanston, IL; University of Wisconsin Comprehensive Cancer Center, Madison, WI; American Medical Center Cancer Research Center, Denver, CO; Cancer Therapy and Research Center, San Antonio, TX; Dana-Farber Cancer Center, Boston, MA; and Vanderbilt University, Nashville, TN.

Tóm tắt

PURPOSE: Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non–small-cell lung cancer (NSCLC). To determine whether a new agent, paclitaxel, would further improve survival in NSCLC, the Eastern Cooperative Oncology Group conducted a randomized trial comparing paclitaxel plus cisplatin to a standard chemotherapy regimen consisting of cisplatin and etoposide. PATIENTS AND METHODS: The study was carried out by a multi-institutional cooperative group in chemotherapy-naive stage IIIB to IV NSCLC patients randomized to receive paclitaxel plus cisplatin or etoposide plus cisplatin. Paclitaxel was administered at two different dose levels (135 mg/m2 and 250 mg/m2), and etoposide was given at a dose of 100 mg/m2 daily on days 1 to 3. Each regimen was repeated every 21 days and each included cisplatin (75 mg/m2). RESULTS: The characteristics of the 599 patients were well-balanced across the three treatment groups. Superior survival was observed with the combined paclitaxel regimens (median survival time, 9.9 months; 1-year survival rate, 38.9%) compared with etoposide plus cisplatin (median survival time, 7.6 months; 1-year survival rate, 31.8%; P = .048). Comparing survival for the two dose levels of paclitaxel revealed no significant difference. The median survival duration for the stage IIIB subgroup was 7.9 months for etoposide plus cisplatin patients versus 13.1 months for all paclitaxel patients (P = .152). For the stage IV subgroup, the median survival time for etoposide plus cisplatin was 7.6 months compared with 8.9 months for paclitaxel (P = .246). With the exceptions of increased granulocytopenia on the low-dose paclitaxel regimen and increased myalgias, neurotoxicity, and, possibly, increased treatment-related cardiac events with high-dose paclitaxel, toxicity was similar across all three arms. Quality of life (QOL) declined significantly over the 6 months. However, QOL scores were not significantly different among the regimens. CONCLUSION: As a result of these observations, paclitaxel (135 mg/m2) combined with cisplatin has replaced etoposide plus cisplatin as the reference regimen in our recently completed phase III trial.

Từ khóa


Tài liệu tham khảo

10.3322/canjclin.49.1.8

10.1200/JCO.1993.11.10.1866

10.1136/bmj.311.7010.899

10.1200/JCO.1985.3.1.72

10.1200/JCO.1986.4.1.14

10.1200/JCO.1989.7.11.1602

10.1093/jnci/85.5.388

10.1093/jnci/85.5.384

10.1200/JCO.1986.4.5.702

Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 15:649,1982-655,

10.2307/2530245

10.1093/biomet/70.3.659

10.1080/01621459.1952.10483441

10.1080/01621459.1958.10501452

Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163,1966-170,

Longnecker SM, Donehower RC, Cates WE, et al: High performance liquid chromatographic assay for Taxol (NSC 125973) in human plasma and urine pharmacokinetics in a phase I trial. Cancer Treat Rep 71:53,1981-59,

10.1200/JCO.1993.11.10.2010

10.1016/0169-5002(95)00450-F

10.1002/(SICI)1097-0258(19980315/15)17:5/7<781::AID-SIM821>3.0.CO;2-O

Aisner J, Hansen HH: Commentary: Current status of chemotherapy for non-small cell lung cancer. Cancer Treat Rep 65:979,1981-986,

10.1200/JCO.1998.16.6.2133

Shepherd F, Ramlau R, Mattson K, et al: Randomized study of taxotere (tax) versus best supportive care (BSC) in non–small-cell lung cancer (MSCLC) patients previously treated with platinum-containing chemotherapy. Proc Am Soc Clin Oncol 18:463a,1999 (abstr 1784)

Gatzemeier U, Von Pawel J, Gottfield M, et al: Phase III comparative study of high-dose cisplatin versus a combination regimen of paclitaxel and cisplatin in patients with advanced non–small-cell lung cancer. Proc Am Soc Clin Oncol 17:454a,1998 (abstr 1748)

Belani CP, Natale RB, Lee JS, et al: Randomized phase III trial comparing cisplatin-etoposide versus carboplatin-paclitaxel in advanced and metastatic non–small-cell lung cancer. Proc Am Soc Clin Oncol 17:455a,1998 (abstr 1751)

10.1097/00001813-199704000-00011

Kelly K, Pan Z, Murphy J, et al: A phase I trial of paclitaxel plus carboplatin in untreated patients with advanced non-small cell lung cancer. Clin Cancer Res 3:1117,1997-1123,

10.1200/JCO.1997.15.1.317

Kelly K, Crowley J, Bunn PA, et al: A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group trial. Proc Am Soc Clin Oncol 18:461a,1999 (abstr 1777)

10.1200/JCO.1998.16.7.2459

Thông tin
Thông tin xuất bản

American Society of Clinical Oncology (ASCO)

Tập 18 Số 3

623-623

Thông tin tác giả